A Phase 3 interventional study of Fluticasone Propionate and Salmeterol Inhalation Powder and Fluticasone Propionate and Salmeterol Inhalation Powder in Asthma, sponsored by Actavis Inc.. Completed at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-24.
Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. — none open to participants now, 1 under way, 1 of them phase 3. Asthma · Teva Pharmaceutical Industries, Ltd..
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 5th largest by enrollment of the 51 interventional ones that give a count, is the only one that started in 2018, is one of 30 in phase 3, and was the 46th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →None of the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Asthma, anywhere →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 999 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 317 across the 51 interventional studies, 1,025 across the 2 observational. Of the 52 that completed or were terminated, 36 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Actavis Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Actavis Inc. is the lead sponsor of 95 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
1 of the studies in Asthma by Teva Pharmaceutical Industries, Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, multiple-dose, blinded, placebo-controlled, parallel-group, multiple-center bioequivalence study with pharmacodynamic endpoints
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects who are of non- must meet one of the following criteria:
Females of childbearing potential must not be pregnant or lactating at Screening or Randomization as confirmed by a negative serum pregnancy test with a sensitivity of 25 mIU/mL of human chorionic gonadotropin at Screening, and a negative urine pregnancy test with a sensitivity of less than 50 mIU/mL at all other visits. The subject may enter the placebo run-in period prior to receipt of test results at Screening, if not yet received from the clinical laboratory, but should be evaluated by the Investigator for continued participation once test results are received.
Women of childbearing potential must agree to the use of a reliable method of (e.g., total abstinence, intrauterine device, a double-barrier method, oral, transdermal, injected or implanted non- or hormonal contraceptive), throughout the study. A sterile sexual partner is not considered an adequate form of birth control. Subjects on hormonal contraceptives must have been on the same hormonal contraceptive for at least one month before the Screening and continue throughout the duration of the study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg
Drug: Fluticasone Propionate and Salmeterol Inhalation Powder
ADVAIR DISKUS® 100/50 (fluticasone propionate and salmeterol) Inhalation Powder
Drug: Fluticasone Propionate and Salmeterol Inhalation Powder
Placebo
Drug: Placebo Inhalation Powder
100/50 mcg per actuation
100/50 mcg per actuation
Also known as: ADVAIR DISKUS®
No active content
Baseline-adjusted Area Under the Serial FEV1-time Curve Calculated From Time Zero to 12 Hours (AUC0-12h) on Day 1 of Treatment
Baseline-adjusted area under the serial FEV1-time curve calculated from time zero to 12 hours (AUC0-12h) on Day 1 of treatment. LSMeans will be used for the statistical analysis. Only the active treatments (test and reference) are compared in this analysis. The placebo arm was used in superiority analysis only.
Time frame: 12 hours
Baseline-adjusted Pre-dose FEV1 Measured in the Morning Following 28 Days of Treatment.
Baseline-adjusted pre-dose FEV1 measured in the morning following 28 days of treatment. Only the active treatments (test and reference) are compared in this analysis. The placebo arm was used in superiority analysis only.
Time frame: 28 days
Statistical Superiority of Test and Reference Over Placebo Treatment in Baseline-adjusted Area Under the Serial FEV1-time Curve
Statistical Superiority of Test and Reference over Placebo Treatment in Baseline-adjusted area under the serial FEV1-time curve
Time frame: 12 hours
Statistical Superiority of Test and Reference Over Placebo Treatment in Baseline-adjusted Pre-dose FEV1 Measured in the Morning Following 28 Days of Treatment
Statistical Superiority of Test and Reference over Placebo Treatment in Baseline-adjusted pre-dose FEV1 measured in the morning following 28 days of treatment
Time frame: 28 days
| Milestone | Test | Reference | Placebo |
|---|---|---|---|
| Started | 485 | 413 | 101 |
| Completed | 472 | 402 | 94 |
| Not completed | 13 | 11 | 7 |
| Withdrew: Adverse event | 2 | 2 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 3 | 3 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 1 |
| Withdrew: Significant worsening of condition requiring therapy | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 4 | 1 | 0 |
| Withdrew: Other reasons | 2 | 4 | 0 |
Baseline-adjusted area under the serial FEV1-time curve calculated from time zero to 12 hours (AUC0-12h) on Day 1 of treatment. LSMeans will be used for the statistical analysis. Only the active treatments (test and reference) are compared in this analysis. The placebo arm was used in superiority analysis only.
| liters x hours | Test | Reference |
|---|---|---|
| Baseline-adjusted Area Under the Serial FEV1-time Curve Calculated From Time Zero to 12 Hours (AUC0-12h) on Day 1 of Treatment | 4.03 ± 0.17 | 3.96 ± 0.18 |
Baseline-adjusted pre-dose FEV1 measured in the morning following 28 days of treatment. Only the active treatments (test and reference) are compared in this analysis. The placebo arm was used in superiority analysis only.
| Liters | Test | Reference |
|---|---|---|
| Baseline-adjusted Pre-dose FEV1 Measured in the Morning Following 28 Days of Treatment. | 0.33 ± 0.02 | 0.34 ± 0.02 |
Statistical Superiority of Test and Reference over Placebo Treatment in Baseline-adjusted area under the serial FEV1-time curve
| liters x hours | Test | Reference | Placebo |
|---|---|---|---|
| Statistical Superiority of Test and Reference Over Placebo Treatment in Baseline-adjusted Area Under the Serial FEV1-time Curve | 4.02 ± 0.17 | 3.94 ± 0.18 | 1.21 ± 0.35 |
Statistical Superiority of Test and Reference over Placebo Treatment in Baseline-adjusted pre-dose FEV1 measured in the morning following 28 days of treatment
| Liters | Test | Reference | Placebo |
|---|---|---|---|
| Statistical Superiority of Test and Reference Over Placebo Treatment in Baseline-adjusted Pre-dose FEV1 Measured in the Morning Following 28 Days of Treatment | 0.33 ± 0.02 | 0.33 ± 0.02 | 0.11 ± 0.04 |
Collected over AEs were collected from each subject from the time of ICF signature until the end of study. Total duration for each subject was approximately 3-4 months.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test | 0/485 (0%) | 0/485 (0%) | 3/485 (0.6%) |
| Reference | 0/413 (0%) | 2/413 (0.5%) | 1/413 (0.2%) |
| Placebo | 0/101 (0%) | 0/101 (0%) | 5/101 (5%) |
| Event | Test | Reference | Placebo |
|---|---|---|---|
| Ischaemic StrokeNervous system disorders | 0/485 | 1/413 | 0/101 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/485 | 1/413 | 0/101 |
| Event | Test | Reference | Placebo |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 3/485 | 1/413 | 5/101 |
Safety Population
| Age, Continuous(years) | Test | Reference | Placebo | Total |
|---|---|---|---|---|
| Mean | 43.8 ± 16.01 | 45.2 ± 16.87 | 48.1 ± 16.91 | 45.7 ± 16.60 |
| Sex: Female, Male(Participants) | Test | Reference | Placebo | Total |
|---|---|---|---|---|
| Female | 305 | 251 | 60 | 616 |
| Male | 180 | 162 | 41 | 383 |
| Ethnicity (NIH/OMB)(Participants) | Test | Reference | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 191 | 158 | 37 | 386 |
| Not Hispanic or Latino | 294 | 255 | 64 | 613 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Test | Reference | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 5 | 6 | 1 | 12 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 0 | 3 |
| Black or African American | 79 | 70 | 14 | 163 |
| White | 395 | 331 | 84 | 810 |
| More than one race | 3 | 4 | 2 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Asthma History (years)(years) | Test | Reference | Placebo | Total |
|---|---|---|---|---|
| Mean | 29.2 ± 15.87 | 30.4 ± 16.50 | 32.6 ± 17.09 | 30.7 ± 16.49 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — No participant data will be shared.
Ran from Dec 2018 to primary completion in Oct 2019, 10 months.
Results were first posted in Sep 2021, 1 year 10 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 10 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.